Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer

Current Cancer Drug Targets

Volumn 13, Issue 2, 2013, Pages 121-125

  Bu, Zhaode ^a,b   Ji, Jiafu ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Everolimus; Gastric cancer; mTOR inhibitors

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RAPAMYCIN; SOMATOMEDIN RECEPTOR;

ANEMIA; ANOREXIA; APPETITE; ARTICLE; BRAIN INFARCTION; CELL PROLIFERATION; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FATIGUE; GASTRECTOMY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; ILEUS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LEUKOPENIA; LIVER DISEASE; LYMPHOCYTOPENIA; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TUMOR BLEEDING; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM METASTASIS; SIROLIMUS; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84876827588     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313020002     Document Type: Article

References (36)

1. Jemal, A.; Bray F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61 (2), 69-90.
2. Yang, D.; Hendifar, A.; Lenz, C.; Togawa, K.; Lenz, F.; Lurje, G.; Pohl, A.; Winder, T.; Ning, Y.; Groshen, S.; Lenz, H. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J. Gastrointest. Oncol. 2011, 2 (2), 77-84.
3. Gastric Cancer Diagnosis and Treatment Expert Panel of the Chinese Ministry of Health. Chinese guidelines for diagnosis and treatment of gastric cancer (2011 edition). Transl. Gastrointest. Cancer 2012, 1 (1), 103-114.
4. Popiela, T.; Kulig, J.; Kolodziejczyk, P.; Sierzega, M. Long-term results of surgery for early gastric cancer. Br. J. Surg. 2002, 89 (8), 1035-1042.
5. Kim, G. M.; Chung, H. C. The first step on earth: a small step for a trial, a giant leap for mankind. Transl. Gastrointest. Cancer 2012, 1 (1), 115-116.
6. Hartgrink, H. H.; van de Velde, C. J.; Putter, H. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 2004, 22 (11), 2069-2077.
7. Jain, V. K.; Cunningham, D. Targeting angiogenesis in advanced gastric cancer: Is this end of the road? Transl. Gastrointest. Cancer 2012, 1 (1), 119-121.
8. Hopkins, S.; Yang, G. FDG PET imaging in the staging and management of gastric cancer. J. Gastrointest. Oncol. 2011, 2 (1), 39-44.
9. Ross, P.; Nicolson, M.; Cunningham, D. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venousinfusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 2002, 20 (8), 1996-2004.
10. Dank, M.; Zaluski, J.; Barone, C. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann. Oncol. 2008, 19 (8), 1450-1457.
11. Jimenez, P.; Pathak, A.; Phan, A. The role of taxanes in the management of gastroesphageal cancer. J. Gastrointest. Oncol. 2011, 2 (4), 240-249.
12. Van Cutsem, E.; Moiseyenko, V. M.; Tjulandin, S. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 2006, 24 (31), 4991-4997.
13. Jensen, K.; Afroze, S.; Munshi, M. K.; Guerrier, M.; Glaser S. S. Mechanisms for nicotine in the development and progression of gastrointestinal cancers. Transl. Gastrointest. Cancer 2012, 1 (1), 81-87.
14. Bjornsti, M. A.; Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4 (5), 335-348.
15. Hildebrandt, M. A.; Yang, H.; Hung, M. C.; Izzo, J. G.; Huang, M.; Lin, J.; Ajani, J. A.; Wu, X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J. Clin. Oncol. 2009, 27 (6), 857-871.
16. Velho, S.; Oliveira, C.; Ferreira, A. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur. J. Cancer 2005, 41 (11), 1649-1654.
17. Di Nicolantonio, F.; Arena, S.; Tabernero, J. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest. 2010, 120 (8), 2858-2866.
18. Meric-Bernstam, F.; Gonzalez-Angulo, A. M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27 (13), 2278-2287.
19. Martin, M. E.; Perez, M. I.; Redondo, C.; Alvarez, M. I.; Salinas, M.; Fando, J. L. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int. J. Biochem. Cell. Biol. 2000, 32 (6), 633-642.
20. Yu, G.; Wang, J.; Chen Y. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin. Cancer Res. 2009, 15 (5), 1821-1829.
21. An, J. Y.; Kim, K. M.; Choi, M. G. Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int. J. Cancer 2010, 126 (12), 2904-2913.
22. Murayama, T.; Inokuchi, M.; Takagi, Y. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br. J. Cancer 2009, 100 (5), 782-788.
23. Taguchi, F.; Kodera, Y.; Katanasaka, Y.; Yanagihara, K.; Tamura, T.; Koizumi, F. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest. New Drugs 2011, 29 (6), 1198-1205.
24. Cejka, D.; Preusser, M.; Fuereder, T. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res. 2008, 28 (6A), 3801-3808.
25. Shigematsu, H.; Yoshida, K.; Sanada, Y. Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells. Int. J. Cancer 2010, 126 (11), 2716-2725.
26. Okamoto, I.; Doi, T.; Ohtsu, A. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn. J. Clin. Oncol. 2010, 40 (1), 17-23.
27. Doi, T.; Muro, K.; Boku, N. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol. 2010, 28 (11), 1904-1910.
28. Yeh, K. H.; Van Cutsem, E.; Ohtsu, A.; Shen, L.; Ajani, J. A.; Rizvi, S.; Sedova, M.; Costantini, C.; Smith, H.; Sahmoud, T.; Bang, Y. J. Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study. J. Clin. Oncol. 2012, 30, (suppl; abstr 4081).
29. Fuereder, T.; Wanek, T.; Pflegerl, P. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin. Cancer Res. 2011, 17 (16), 5233-5332.
30. Bhattacharya, B.; Akram, M.; Balasubramanian, I. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target ofrapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cells. Cancer Biol Ther. 2012, 13 (1), 34-42.
31. Al-Batran, S. E.; Ducreux, M.; Ohtsu. A. mTOR as a therapeutic target in patients with gastric cancer. Int. J. Cancer 2012, 130 (3), 491-496.
32. Sarbassov, D. D.; Ali, S. M.; Sengupta, S.; Sheen J. H.; Hsu, P. P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 2006, 22 (2), 159-168.
33. Wander, S. A.; Hennessy, B. T.; Slingerland, J. M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 2011, 121 (4), 1231-1241.
34. Dowling, R. J.; Topisirovic, I.; Fonseca, B. D.; Sonenberg, N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta. 2010, 1804 (3), 433-439.
35. Furic, L.; Livingstone, M.; Dowling, R. J.; Sonenberg, N. Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses. Curr. Oncol. 2009, 16 (1), 59-61.
36. Feldman, M. E.; Apsel, B.; Uotila, A. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7(2), e38.